Cargando…
Are new antiretroviral treatments increasing the risks of clinical obesity?
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant. The effects of integrase inhibitors on body weight need to be analysed f...
Autores principales: | Hill, Andrew, Waters, Laura, Pozniak, Anton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mediscript Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362910/ https://www.ncbi.nlm.nih.gov/pubmed/30800425 |
Ejemplares similares
-
Intersecting HIV and mpox epidemics: more questions than answers
por: Girometti, Nicolo, et al.
Publicado: (2022) -
Obesity and chronic diarrhea: a new syndrome?
por: Linghu, Enqiang
Publicado: (2022) -
Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All
por: Ford, Nathan, et al.
Publicado: (2018) -
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
por: Fidler, S., et al.
Publicado: (2020) -
HIV psychiatry in the era of combined antiretroviral therapy: top five issues
por: Zirulnik, Jorge L, et al.
Publicado: (2015)